10 Top Performing European Stocks Heading into 2025

6) NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS)

% Increase on a YTD Basis: ~101%

Average Upside Potential: ~51.3%

NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) is a late-stage biopharmaceutical company, which is engaged in developing therapies to enhance patient care in populations with metabolic disease. The company is headquartered in Naarden, the Netherlands.

NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) continues to make significant strides in its clinical trials. It demonstrated successful outcomes from its Phase 3 BROOKLYN clinical trial, which exhibited a substantial reduction in low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolemia. The drug obicetrapib, which was evaluated in the trial, exhibited a significant ability to reduce LDL-C levels. Wall Street analysts are confident in obicetrapib’s clinical profile and its potential to improve patients’ health outcomes.

NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS)’s patent portfolio for obicetrapib is robust, with a method of use and dose selection patents anticipated to offer market exclusivity until the late 2030s. This strong IP position should help the company to garner substantial tail revenues. The drug’s convenience profile, along with potential metabolic benefits, should act as a key differentiator in the competitive landscape of cholesterol-lowering treatments.

Wall Street analysts believe that the drug’s broad benefits, such as its efficacy in lowering LDL-C and Lp(a), and its potential use in diabetic patients, should further strengthen its market appeal.  NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) recognized $29.1 million in revenue for Q3 2024 as compared to $2.9 million in the same period of 2023. This rise was mainly because of the achievement of a clinical development milestone from Menarini during the current period.

Analysts at Piper Sandler restated an “Overweight” rating on the shares of NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS), issuing a $37.00 price target on 23rd September.